Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 17.81 3.37% 0.58
RVNC closed up 3.37 percent on Friday, January 18, 2019, on 2.26 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RVNC trend table...

Date Alert Name Type % Chg
Jan 18 Slingshot Bearish Bearish Swing Setup 0.00%
Jan 18 Lower Bollinger Band Walk Weakness 0.00%
Jan 18 Stochastic Reached Oversold Weakness 0.00%
Jan 18 Lower Bollinger Band Touch Weakness 0.00%
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 MACD Bearish Signal Line Cross Bearish 3.37%
Jan 17 New 52 Week Closing Low Bearish 3.37%
Jan 17 Volume Surge Other 3.37%
Jan 17 New 52 Week Low Weakness 3.37%
Jan 17 Below Lower BB Weakness 3.37%

Older signals for RVNC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.
Is RVNC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 35.05
52 Week Low 16.76
Average Volume 402,124
200-Day Moving Average 25.9267
50-Day Moving Average 20.5989
20-Day Moving Average 19.2673
10-Day Moving Average 19.2385
Average True Range 1.045
ADX 17.06
+DI 17.7867
-DI 32.9344
Chandelier Exit (Long, 3 ATRs ) 17.695
Chandelier Exit (Short, 3 ATRs ) 19.895
Upper Bollinger Band 21.0538
Lower Bollinger Band 17.4808
Percent B (%b) 0.09
BandWidth 18.544373
MACD Line -0.6278
MACD Signal Line -0.48
MACD Histogram -0.1478
Fundamentals Value
Market Cap 548.89 Million
Num Shares 30.8 Million
EPS -3.44
Price-to-Earnings (P/E) Ratio -5.18
Price-to-Sales 2609.34
Price-to-Book 4.85
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.30
Resistance 3 (R3) 19.27 18.76 19.05
Resistance 2 (R2) 18.76 18.38 18.77 18.96
Resistance 1 (R1) 18.28 18.14 18.52 18.31 18.88
Pivot Point 17.77 17.77 17.89 17.78 17.77
Support 1 (S1) 17.29 17.39 17.53 17.32 16.74
Support 2 (S2) 16.78 17.15 16.79 16.66
Support 3 (S3) 16.30 16.78 16.57
Support 4 (S4) 16.33